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Natural killer (NK) cells are innate immune lymphocytes that function mainly as immune
sentinels against viral infection and tumorigenesis. NK cell function is governed by inhibitory
and activating signals arising from corresponding receptors. A prominent group of activating
NK receptors is the natural cytotoxicity receptors (NCRs), which includes NKp30, NKp44,
and NKp46. These receptors bind various diverse ligands of pathogenic, tumor, and even
self origin. Type 1 diabetes mellitus (T1D) is a multifactorial autoimmune disease, in which
insulin-producing beta (β) cells are ablated by the immune system. This killing of β cells is
carried out mainly by T cells, but many other immune cells have been implicated in the
pathogenesis of this disease. Importantly, NK cells were shown to be key participants in
the initial autoimmune attack. It was shown that all β cells from humans and mice, healthy
or sick, express an unknown ligand for the activating NKp46 receptor. In this review, we
describe the role played by the NCRs in various pathologies with an emphasis on Type I
diabetes.
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Natural killer (NK) cells are innate immune cells that differentiate,
like T- and B-lymphocytes, from the common lymphoid progen-
itor, in the bone marrow. In 1975, NK cells were described to
have an intrinsic capacity to rapidly kill tumor cells (1, 2). Subse-
quent research revealed that these cytotoxic responses could also
be elicited by virally infected non-tumor cells (3). Additionally, NK
cells have been recognized to be major producers of Interferon-γ,
in both pathological and physiological states. NK cells also pro-
duce a variety of other cytokines, both pro-inflammatory (such
as tumor necrosis factor-α) and immunosuppressive (such as
interleukin-10, IL-10) (4). Indeed, in addition to their role in
eliminating pathogen-infected and -transformed cells, NK cells
have also been implicated in autoimmune responses, primarily
as immune-regulators that can limit or enhance the autoimmune
response, both via cytokine signaling and direct interactions with
other immune cells. The role of NK cells has been investigated
in several different autoimmune conditions including: systemic
lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and
Type I diabetes (T1D) (5–10).
Natural killer cells, which serve as innate immune sentinels, are
found throughout the body in both lymphoid and non-lymphoid
tissues. While they reside mainly in the peripheral blood (where
they represent 2–18% of the lymphocytes in humans), liver (where
NK cells can represent up to 50% of the resident lymphocytes),
and spleen, they are also found in the skin, in mucosal tissues
such as the lung, in the uterine decidua (11) (where they play a
key roles in promoting trophoblast invasion and arterial growth)
as well as many other tissues. In addition to their functional
role in peripheral non-lymphoid tissues, NK cells can also pro-
liferate and undergo maturational processes in these locations
(7, 11–15).
Human NK cells are generally classified into two subgroups
based on the expression of CD56 and CD16, which roughly
correspond to their activation state. Most circulating NK cells
are CD56dimCD16+ and are considered to be activated. In this
state, when NK cells recognize their target cells, they respond by
either killing the target or by producing and releasing cytokines.
In contrast, CD56hiCD16− NK cells, which represent the major
population of NK cells found in peripheral lymphoid tissues (16)
and in the decidua, respond to stimulation by pro-inflammatory
cytokines by producing large amounts of cytokines and acquire
cytotoxicity only after prolonged activation. It has been well estab-
lished that the “immature” CD56hiCD16− NK cells differentiate
into the more active CD56dimCD16+ state, which in turn can
differentiate and mature further (7, 17–24).
Natural killer cell activity is governed by a delicate balance
between activating and inhibitory signals, which arise from corre-
sponding activating and inhibitory receptors. Unlike the antigen-
specific, somatically recombined receptors found on T- and B-
lymphocytes, NK cell receptors are germline encoded and the
activating receptors are of limited repertoire (25).
The inhibitory NK receptors, which predominantly recog-
nize major histocompatibility complex 1 (MHC1, or human
leukocyte antigen – HLA) proteins, consist of several recep-
tor subgroups. The largest of these groups is the killer-cell
immunoglobulin-like receptor (KIR) in humans, in which two or
three immunoglobulin-like domains in the extracellular portion
of the receptors recognize specific MHC1 alleles differentially. The
KIR genes are organized in a highly polymorphic, multigene fam-
ily that displays considerable allelic polymorphism and though
both activating and inhibitory KIRs exist, the inhibitory alleles are
more prevalent (26). Other MHC1 recognizing receptors include
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the leukocyte immunoglobulin-like receptor subfamily B mem-
ber 1 (LIR1) and the NKG2A-CD94 receptor complex. Moreover,
NK cell tolerance toward normal cells is achieved through the
expression of MHC1-binding inhibitory receptors by the NKs.
Thus, cells that evade cytotoxic CD8+ T-cell recognition and
killing by downmodulating the expression of MHC1, render them-
selves potential targets for NK cell mediated elimination. In addi-
tion, several other inhibitory receptors, which bind to non-MHC1
ligands exist, including CEACAM1, CD300a, and TIGIT (26–31).
All the different inhibitory receptors contain one or more intracel-
lular immunoreceptor tyrosine-based inhibitory motifs (ITIMs),
which mediate the downstream inhibitory signals by recruiting
protein tyrosine phosphatases (32). MHC1 molecules also edu-
cate the NK cells to become functionally competent, and NK cells
function poorly in the absence of MHC1 (33).
The activating NK cell receptors recognize tumor-, pathogen-,
stress-induced, and self-ligands. Unlike the inhibitory recep-
tors, many of the activating NK receptors lack intracellular
signaling motifs. Instead, upon binding to their various lig-
ands, these receptors, which belong to various receptor groups,
recruit immunoreceptor tyrosine-based activating motif (ITAM)-
containing adapters, such as: DAP10, DAP12, FcεRIγ, or CD3ζ,
which in turn mediate tyrosine-kinase based downstream signal-
ing (28, 31). The most prominent NK cell activating receptors
are the natural cytotoxicity receptor (NCR) family, which includes
three Ig-like proteins: NKp30 (34), NKp44 (35), and NKp46 in
humans (36, 37). Of these, NKp46 and NKp30 are constitutively
expressed by all NK cells, while NKp44 is expressed only after
activation. The gene coding for NKp46 is located in the leukocyte-
receptor complex on human chromosome 19, while the genes
for NKp44 and NKp30 are located on chromosome 6. Upon
binding their respective ligands, the NCRs recruit different ITAM-
containing adapters to initiate signal transduction: NKp46 can
recruit FcεRIγ and CD3ζ, the latter of which is also recruited by
NKp30, while NKp44 recruits the adapter DAP12 (28, 38, 39).
Like many of the other activating NK receptors, the NCRs rec-
ognize tumor and self-ligands, yet, to-date they are the only NK
receptors which have been found to directly recognize pathogen-
derived molecules (28). Indeed, the first NCR ligands recognized
were the influenza virus hemagglutinin (HA) and the Sendai virus
HA-neuraminidase, which are recognized by NKp46 and NKp44
(28, 40). NKp46 also recognizes unknown ligand/s expressed by
Fusobacterium nucleatum (41) and Mycobacterium tuberculosis,
NKp44 recognizes the E-protein of Dengue virus and West Nile
virus as well as bacterial cell wall components of Pseudomonas
aeruginosa, Nocardia spp., and Mycobacteria spp. (42). NKp30
recognizes the PfEMP-1 protein of Plasmodium falciparum (43)
and has recently been shown to bind and mediate the killing of
various fungal species (44). Poxvirus HA has also been recognized
as a target NKp46 and NKp30 (45). Yet, in the case of NKp30,
the poxvirus HA serves as an inhibitory ligand, as is also the case
with the pp65 protein of HCMV (46). In addition to recogniz-
ing pathogen expressed ligands, the NCRs also recognize several
other known ligands, including Heparan sulfates, which are rec-
ognized differentially by the different NCRs, (47) as well as BAT3
(expressed by stressed cells) and B7-H6 (expressed by tumor cells),
which are recognized by NKp30, (48, 49) and MLL5, which has
recently been identified as a tumor expressed protein ligand of
NKp44 (16). In addition, all the NCRs recognize unknown lig-
ands expressed constitutively by several types of hematopoietic
cells (granulocytes, monocytes, and dendritic cells). The recip-
rocal interaction between these cells and NK cells can result in
their mutual activation or, alternatively, this interaction can some-
times lead to NK cell-mediated killing of immature dendritic
cells (50–53).
NKp46 is unique amongst the NCRs and is considered to be the
most specific NK cell marker. NKp46 is also distinct in that it is the
only NCR that has a murine ortholog, named NCR1 (54–56). As
such, NKp46 and NCR1 are the most studied of the NCRs. Mice
knockouts (KO) for the NCR1 gene were generated through the
insertion of a reporter gene, encoding green fluorescent protein
(GFP), into the Ncr1 locus. While the heterozygous Ncr1+/gfp NK
cells are haplo-sufficient and display a wildtype (wt) phenotype in
the homozygous Ncr1gfp/gfp mice, Ncr1 is knocked out and their
NK cells lack NCR1 dependent functions (54, 57). Yet, despite
this powerful, commercially available tool, the tumor and cellular
ligand(s) for NKp46/NCR1 remain unknown.
To address the issue of NKp46 ligand expression, when such
ligands are unknown, fusion proteins containing the extracellu-
lar portion of NKp46 fused to the Fc portion of human IgG1 have
been used for cell and tissue staining. By applying this technique to
murine and human tissue samples, it was found that both human
and murine insulin-producing beta cells (β cells) constitutively
express an NKp46 ligand (57, 58). In addition to β-cells, only two
more normal tissues were found to express an NKp46 ligand(s),
the salivary glands and hepatic stellate cells (57, 59). However,
NKp46 and the other NCRs have also been found to bind to as of
yet unknown ligands, of cellular, bacterial, fungal, and viral origin.
Although the identities of these ligands remain largely unknown,
experimental evidence suggests that each of the NCRs interacts
with several distinct ligands (28).
In addition to the NCRs, NK cells express several other acti-
vating receptors: CD16 which mediates antibody-dependent cell-
mediated cytotoxicity (ADCC); NKG2D which recognizes several
stress-induced ligands expressed by cancerous, virally infected, and
other stressed cells; as well as several receptors including NKp80,
2B4, DNAM1, NKG2C, and some short tailed KIRs that recognize
ligands expressed physiologically on different cell types. In this
regard it is important to note that all the activating NK receptors,
with the exception of CD16, have been shown to be insufficient on
their own in stimulating NK cell cytolytic functions (27, 28, 31).
Thus,NK cell populations,which variably express different acti-
vating and inhibitory receptors, may respond differentially upon
encountering a potential target cell. However, the underlying prin-
ciples that control NK cell activation remain the same: activating
signals emanating from their corresponding receptors (mediated
by tyrosine-kinase based signal transduction pathways), are inte-
grated with repressive signals from inhibitory receptors (mediated
by protein phosphatases), culminating in either target cell killing
or in unresponsiveness (27, 60).
In the following segments, we will describe the involvement of
NK cells in general and NKp46 specifically in T1D to exemplify the
complexity of studying the roles of NCRs in human disease. T1D
is a multifactorial autoimmune disease in which insulin producing
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β cells, which reside in the islets of Langerhans in the pancreas, are
attacked and killed predominantly by autoreactive T lymphocytes.
Indeed, adoptive transfer experiments of T cells from diabetic
mice to non-diabetics, confers diabetes via the killing of β cells
in the recipient (61). However, other immune cells have also been
implicated in diabetes pathogenesis (Figure 1): antibody produc-
ing B-lymphocytes have been implicated in maintaining T-cell
reactivity toward β cells (62); macrophages, which are recruited
to the islets of Langerhans in non-obese diabetic mice (NOD, the
most studied animal model for T1D), prior to T-cell arrival, have
been shown to be critical for diabetes progression (63); in addition,
NK cells have also been implicated in T1D pathogenesis.
The first reports linking NK cells to diabetes came in the 1980s
and early 1990s. These reports found that the NK cells from
diabetic and diabetic prone rats were more cytotoxic than their
counterparts from diabetic resistant rats, from the same genetic
backgrounds (65–67). The next reports linking NK cells to diabetes
came when experiments demonstrated that antibody-dependent
depletion of NK cells (using an anti-asialo GM1 antibody, which
depletes NK cells, with “off-target” effects on T cells and basophils
(68)) could prevent diabetes development in two separate chemi-
cally induced diabetes models: low-dose streptozotocin (LDST)
and cyclophosphamide (69, 70). Regardless, in both cases the
experiments were conducted in mice, thus widening the scope and
validity of the original findings: NK cells were not only capable
of killing islet cells, but also seemed to be important in diabetes
development in two distinct experimental models. When NOD
mice from two genetic backgrounds were studied, one of which
develops severe insulitis (inflammation in the islets of Langerhans)
that rarely develops into diabetes and the other, which develops
insulitis that rapidly progresses to diabetes, it was found that the
main difference was a higher proportion of NK cells in the early
insulitis immune infiltrates of the diabetes prone mice (71).
As for activating NK receptor presentation in T1D patients,
while reduced NKp46 and NKp30 levels were observed only in
patients with long-standing disease, a reduction in NKG2D was
observed in both newly diagnosed and long-standing patients (72,
73). Moreover, the prevalence of activating KIR genes was higher
in T1D patients when compared to HLA-matched controls. As the
KIR repertoire expressed by NK cells determines self-tolerance and
affects T-cell function, it would indeed be reasonable that the KIR
genes influence susceptibility to T1D (73–75). Thus, NK cells were
implicated in diabetes development both in animal models and
human patients.
The first mechanistic link between NK cells and diabetes was
the discovery that β cells from healthy mice, NOD mice, Psam-
momys obesus, and humans all express an NKp46 ligand (57, 58,
76). Although the identity of this ligand still remains unknown,
some insights into the biology of the ligand and its interactions
with NKp46 and NCR1 have been gained. It was found that two
glycosylated amino acid residues located in the extracellular seg-
ment of NKp46, Thr125 and the Asn216, are critical for binding this
ligand (58). Importantly, binding of NKp46 to influenza virus HA
is dependent on a different glycosylated residue – Thr225. With
regards to the expression kinetics of the β cell ligand for NKp46,
it was shown that in both adult and young, mice and humans, the
FIGURE 1 |Various immune cells are involved in T1D pathogenesis.
Cytotoxic CD8+ T cells mediate most of the direct β cell killing, while CD4+
T cells help in maintaining their reactivity. Macrophages (Mθ) release tumor
necrosis factor-α (TNFα), IL1β, and other cytokines, which cause β cell stress
and promote cell death, in turn contributing to the local inflammation.
Moreover, Mθ promote CD8+ T-cell differentiation mediated both by direct
interactions and in Trans by cytokines. Local inflammation, β cell stress, and
the expression of an unknown ligand for NKp46 contribute to NK cell
reactivity toward β cells, which have been shown to kill β cells. In addition, β
cells have been shown to exhibit abnormal interferon (IFN) responses when
infected by viruses (64), thus potentially contributing even further to NK
mediated killing.
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ligands are expressed constitutively. However, while human β cells
display ligand expression even at the earliest embryonic stages in
which insulin is expressed, the murine ligand is not expressed by
embryonic β cells. Nonetheless, following birth (as early as day 1
post-partum) the NKp46 ligand is expressed by all murine β cells.
One possible explanation for the differences in ligand expression
between human and murine β cells is that the NKp46 ligand is
somehow associated with functional maturation of the β cells,
which occurs relatively earlier during human pregnancy (58).
Moreover, the β-cell ligand expression was found to be closely
correlated with β cell function. It was found to be present mainly in
the insulin granules and to be released to the plasma membrane as
β cells degranulate and release insulin. It was also shown that when
β cell function starts to falter, as it happens during Type 2 diabetes
development, the β cell NKp46 ligand expression is mostly lost,
only to return to normal levels if the Type 2 diabetic phenotype is
reversed (76).
The expression of the NKp46 ligand is stable in functional β
cells and is maintained in the β cells that survive the immune
attack in pre-diabetic and diabetic NOD mice. Ligand expression
is also maintained during experimental ablation of β cells: it is
maintained in the β cells that survived cytotoxic death mediated by
diphtheria toxin A and is also seen during subsequent β cell regen-
eration. Thus, because of the expression of the NKp46 ligand is
stable and is seen in all functional β cells examined, β cells are con-
stantly at risk of being attacked by NK cells via NKp46-mediated
activation (58, 77).
Indeed, the outcome of β cell recognition by NK cells was exem-
plified in a series of experiments (58, 59). In agreement with earlier
reports from rat NK cell (65), the incubation of human or mouse
β cells with their corresponding NK cells caused NK cell degran-
ulation as well as direct killing of the target β cells, as assessed
by radioactive killing assays. Importantly, this β cell induced
NK degranulation was NKp46 dependent as it was significantly
lower in NK cells derived Ncr1gfp/gfp when compared to NK cells
from control Ncr1+/gfp mice. Moreover, in agreement with ear-
lier results, human NK cells killed human β cells and this killing
was impeded by blocking NKp46 (using anti-NKp46 sera). Thus
human and murine β cells are indeed in vitro targets for isolated
NK cells, and are killed NKp46 dependently (58).
Additionally, NK cells and NKp46 were also implicated in T1D
pathogenesis in vivo. NK cells isolated from pre-diabetic NOD
islet immune infiltrates, stained for CD107a expression, which
is a marker for recent NK cell degranulation (78). Moreover,
immunization of NOD mice using NKp46-Ig and NCR1-Ig fusion
proteins significantly reduced diabetes incidence, without deplet-
ing the NK cell population (57). NKp46 involvement in T1D was
not specific to NOD mice: when diabetes was induced in WT
and Ncr1gfp/gfp KO mice using a LDST protocol, diabetes devel-
opment was significantly impaired in mice lacking NCR1. Thus,
NK cells and their NKp46 activating receptor facilitate diabetes
development in vivo, both in induced and genetic models of the
disease.
Thus, all functional β cells express a ligand for NKp46 and NK
cells kill them, when encountering β cells. However, diabetes does
not develop in all individuals because NK cells never encounter β
cells under normal conditions [(58) and Figure 2].
Natural killer cell involvement in diabetes and the intrinsic
NKp46 dependent capacity of NK cells to kill β cells highlight
some key aspects of NK cell biology and the roles of the NCRs.
Despite powerful tools such as transgenic mice and fusion proteins,
many cellular ligands remain unknown, some of which are directly
associated with the disease. The identification of the NCR cellular
ligands has so far remained very difficult. This is due in part to the
fact that each NCR has several different ligands, expressed differ-
entially by different cells and tissues. It remains to be seen whether
and how other diseases are influenced by NCRs. Indeed, in the case
of liver stellate cells, NK cell recognition of their cognate NKp46
FIGURE 2 | Pancreatic NK cells in homeostasis and diabetes. Whereas
NK cells are rarely found in the pancreases of normal healthy mice, in the
peri-islet immune insulitis infiltrates of NOD mice, NK cells are found
starting at the earliest stages of insulitis. This explains why diabetes does
not develop in all individuals, despite the intrinsic ability of NK cells to kill β
cells.
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ligand inhibits liver fibrosis (59). Thus, depending on the context
the same NCR can serve to exacerbate disease in one setting and
ameliorate it in another. Presumably, this has to do with different
ligands expression, though this issue remains unclear. Addition-
ally, as the identification of target cells by NK cells is dependent on
multiple receptors and different combinations of receptor engage-
ments elicit different responses by the NK cells, the issue of NK
cell response to target recognition is vastly complicated.
An early view of NK cells and their receptors identified them as
a primordial mechanism of immunity to infectious pathogens and
subsequently, the NK cell receptors were speculated to be pattern
recognition receptors for pathogens (44, 79). However, the finding
that activating NK cell receptors, in general, and the NCRs specifi-
cally, bind several distinct ligands of endogenous origin implicates
NK cells to be more general immune mediators. It appears that
the NCRs are thus general“danger”pattern recognizers that confer
complex activities to NK cells.
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